Natco Pharma Share Price (NATCOPHARM)
Check the latest share price of Natco Pharma, along with the price target, peer comparison, quarterly results, recent news, expert analysis, shareholding pattern, and other key fundamentals to make informed investment decisions.
as on 04:01PM, 13 Jun 2025
NSE
Natco Pharma Stock Performance
Get live Natco Pharma share price, day's high and low, historical returns, and market stats.
Day's Low
Day's High
₹890.75Day's Price Range₹923.852 Week's Low
52 Week's High
₹726.852-Week Price Range₹1,639
| Returns % | |
| 1 Month Return | + 10.24 % |
| 3 Month Return | + 14.02 % |
| 1 Year Return | -24.61 % |
| 3 Year Return | + 36.21 % |
| 5 Year Return | + 50.62 % |
| Market Stats | |
| Previous Close | ₹924.20 |
| Open | ₹896.05 |
| Volume | 12.95L |
| Upper Circuit | ₹1,109.00 |
| Lower Circuit | ₹739.40 |
Natco Pharma Fundamentals & Key Indicators
Check Natco Pharma market cap, PE, PB, PEG ratios, dividend yield, and other key fundamental indicators.
Market Cap
₹16,347.36 Cr
Return on Equity (ROE)
25.38
PE Ratio (TTM)
8.67
Return on capital employed (ROCE)
28.58
Industry PE ratio
57.39
Beta (LTM)
0.82
P/B Ratio
3.05
Dividend Yield
1
PEG Ratio
0.31
Quarterly Earnings Growth YOY
5.1
EPS (TTM)
77.56
Sector
Pharmaceuticals
Book Value
326.99
Technical Analysis
Bullish
View Technical Analysis
How to invest in Natco Pharma?
Investing in Natco Pharma is simple. You can open a free INDstocks investment account on the INDmoney App. Search for Natco Pharma or NATCOPHARM on the app to check live prices of the stock and click on Buy or SIP. You can invest by selecting the number of shares or set up a fixed SIP to invest every month or week.
For example: You can buy 10 shares of Natco Pharma or start an SIP based on the market price on each investment date.
You can easily transfer money to your stock account via the INDmoney app and start investing in stocks like Natco Pharma with just a few clicks!
Natco Pharma Stock's Interest Amongst Investors
Natco Pharma Valuation
Track how Natco Pharma P/E has moved over time to understand its valuation trends.
Natco Pharma in the last 5 years
Lowest (7.09x)
April 9, 2025
Today (8.67x)
June 13, 2025
Industry (57.39x)
June 13, 2025
Highest (90.32x)
April 6, 2022
Today’s Price to Earnings Ratio: 8.67x
Natco Pharma Stock Recommendation
Get updated buy, sell, and hold recommendations by analysts on Natco Pharma.
based on 11 analysts
30.00%
Buy
30.00%
Hold
40.00%
Sell
40% of analysts recommend a 'HOLD' rating for Natco Pharma. Average target price of ₹980.64
Source: S&P Global Market Intelligence
Natco Pharma Share Price Target
Get share price movements and forecasts by analysts on Natco Pharma.
Natco Pharma price forecast by 11 analysts
Upside of7.44%
High
₹1480
Target
₹980.64
Low
₹697
Natco Pharma target price ₹980.64, a slight upside of 7.44% compared to current price of ₹912.7. According to 11 analysts rating.
Excluding Excise Duty and Other Income, represents Net Revenue
Natco Pharma revenue growth forecast
Forecast
Actual
Including amortisation and stock based compensations
Natco Pharma EPS growth forecast
Forecast
Actual
Source: S&P Global Market Intelligence
Natco Pharma Financial Results
Get the annual and quarterly financial summary of Natco Pharma, including revenue, profit, loss and more.
Indices Featuring Natco Pharma Stock
Check stock indices that include Natco Pharma.
Natco Pharma Earnings and Dividends
View detailed summary of the earnings and dividend history of Natco Pharma.
Natco Pharma Ltd Earnings Results
Natco Pharma Ltd’s net profit jumped 5.25% since last year same period to ₹406.60Cr in the Q4 2024-2025. On a quarterly growth basis, Natco Pharma Ltd has generated 205.71% jump in its net profits since last 3-months.
Read More about Earnings ResultsNatco Pharma Ltd Dividends February,2025
In the quarter ending December 2024, Natco Pharma Ltd has declared dividend of ₹1.50 - translating a dividend yield of 0.79%.
Read More about Dividends
Natco Pharma Shareholding Pattern
View the shareholding pattern breakup of promoters, FIIs, DIIs, and retail investors in Natco Pharma.
| Investors | Holdings % | Quarterly Trend | 3M change |
|---|---|---|---|
| Promoter Holdings | 49.56% | 0.00 | |
| Foreign Institutions | 17.49% | 0.00 | |
| Mutual Funds | 1.85% | 0.00 | |
| Retail Investors | 27.29% | 0.00 | |
| Others | 3.8% | 0.00 |
Natco Pharma vs Peers
Compare market cap, revenue, PE, and other key metrics of Natco Pharma with its industry peers.
Company | Analyst View | Market Cap(in ₹ Cr) | 5 Year CAGR | Debt to Asset Ratio | Net Profit(in ₹ Cr) | Yearly Revenue(in ₹ Cr) |
|---|---|---|---|---|---|---|
| HOLD | 16,347.36 | 10.12% | 0.54 | 1,388 | 3,998 | |
| BUY | 14,157.69 | -4.54% | 0.52 | 413 | 2,013 | |
| BUY | 67,394.66 | 9.93% | 0.56 | 3,168 | 29,001 | |
| HOLD | 98,102.78 | 32.58% | 0.64 | 3,854 | 19,547 | |
| BUY | 66,969.38 | 19.17% | 0.53 | NA | NA |
Natco Pharma News & Key Events
Latest news and events in one place to help you make informed investing decisions in Natco Pharma.
Natco Pharma Receives USFDA Observation at API Unit - 13 Jun, 2025
Natco Pharma's Mekaguda API manufacturing facility received one procedural observation from the USFDA following an inspection. The company is committed to addressing the observation comprehensively.Natco Pharma Gains for Third Consecutive Session - 11 Jun, 2025
Natco Pharma Ltd has gained 3.01% today, marking its third consecutive session of increases. The stock is currently priced at Rs 908.15, despite being down 22.31% over the past year. In the last month, it has risen approximately 8.92%. The Nifty Pharma index has also shown positive movement, up 4.53% in the same period.Natco Pharma Reports Strong Q4 Results for March 2025 - 05 Jun, 2025
Natco Pharma's standalone net sales for March 2025 reached Rs 1,157.40 crore, up 19.96% YoY. Net profit rose 22.63% to Rs 428.10 crore, with EBITDA increasing 27.57%. However, shares have declined 39.96% over the last six months.Natco Pharma Reports Strong Q4 Results for March 2025 - 03 Jun, 2025
Natco Pharma's consolidated net sales for March 2025 reached Rs 1,221 crore, up 14.29% YoY. Net profit rose 5.25% to Rs 406.60 crore, with EBITDA increasing by 13.93%. EPS improved to Rs 22.70. However, shares have declined by 37.95% over the last six months.Natco Pharma Rated HOLD with Revised Target - 30 May, 2025
ICICI Securities has downgraded Natco Pharma to HOLD with a target price of Rs 890, citing competitive pressures on gRevlimid and expected revenue declines in FY26. The company plans to invest in R&D and capacity expansion while anticipating growth from new product launches.Natco Pharma Reports Strong Q4 Results Amid Challenges - 28 May, 2025
Natco Pharma's Q4 results show a 5% profit increase to ₹406 crore and a 16% revenue rise to ₹1,287 crore. Despite strong annual performance, the company warns of a challenging FY26 outlook with expected revenue and profit declines due to pricing pressures and geopolitical issues.Natco Pharma Faces Downtrend with Future Rally Potential - 24 May, 2025
Natco Pharma's stock is in a downtrend, potentially falling to ₹650-600 before a long-term rally could push prices up to ₹1,400. Investors have options to sell now or hold while accumulating shares at ₹680, with stop-loss strategies suggested.
Insights on Natco Pharma Ltd
Insights help you understand the recent movement of the company's critical parameters, giving you an overall view of the company.
POSITIVE IMPACTRetail Holding Up
Retail Investor have increased holdings from 26.87% to 27.29% in Mar 2025 quarter
- POSITIVE IMPACT
Price Rise
In the last 7 days, NATCOPHARM stock has moved up by 5.8%
- POSITIVE IMPACT
Revenue Rich
Revenue is up for the last 2 quarters, 651.1 Cr → 1.28K Cr (in ₹), with an average increase of 49.4% per quarter
- POSITIVE IMPACT
Profit Spike
Netprofit is up for the last 2 quarters, 133.0 Cr → 406.6 Cr (in ₹), with an average increase of 67.3% per quarter
NO EFFECTAgainst Peers
In the last 3 years, Torrent Pharmaceuticals Ltd has given 131.1% return, outperforming this stock by 94.9%
- NO EFFECT
Against Peers
In the last 1 year, Divis Laboratories Ltd has given 45.3% return, outperforming this stock by 69.9%
NEGATIVE IMPACTMF Holding Down
Mutual Funds have decreased holdings from 1.92% to 1.85% in Mar 2025 quarter
- NEGATIVE IMPACT
Promoter Holding Down
Promoters have decreased holdings from 49.62% to 49.56% in Mar 2025 quarter
- NEGATIVE IMPACT
FII Holding Down
Foreign Institutions have decreased holdings from 17.94% to 17.49% in Mar 2025 quarter
About Natco Pharma
Revenue: ₹1,221.00Cr as on March 2025 (Q4 FY25)
Net Profit: ₹406.00Cr as on March 2025 (Q4 FY25)
Listing date: 27 Dec, 1995
Chairperson Name: G S Murthy
| Organisation | Natco Pharma Ltd |
| Headquarters | Hyderabad |
| Industry | Pharmaceuticals |
| CEO | G S Murthy |
| E-voting on shares | Click here to vote |
Mutual Funds that own Natco Pharma
Check out the Mutual Funds with significant holdings in Natco Pharma.
FAQs
What is Natco Pharma share price today?
Natco Pharma share price today stands at ₹912.7, Open: ₹896.05, Previous Close: ₹924.2, High: ₹923.8, Low: ₹890.75, 52 Week High: ₹1639, 52 Week Low: ₹726.8.
What is today's traded volume of Natco Pharma?
Today's traded volume of Natco Pharma is 12.95L. Which means that 12.95L shares of Natco Pharma were bought and sold on the stock market during today's trading session.
What is Natco Pharma's market cap today?
Today's market capitalisation of Natco Pharma is ₹16,347.36 Cr. Market cap or market capitalisation is the total value of a company’s outstanding shares in the stock market, calculated by multiplying the current share price by the total number of shares issued by the company.
What is the 52 week high and 52 week low range of Natco Pharma?
Natco Pharma’s 52 week high is ₹1639 and 52 week low is ₹726.8. The current share price of Natco Pharma is ₹912.7, which is -44.31% down from its 52 week high and 25.58% up from its 52 week low.